BIIB
Biogen Inc.
234.68
USD
This page is just a preview of the data found in TrendSpider’s full version
Biogen Inc. stock is down -5.94% since 30 days ago. The next earnings date is Feb 14, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 29 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 3 PUTs, 7 CALLs. 80% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 28 Nov 14:45 | 19 Jan, 2024 | 235.00 | 686 | ||
| 28 Nov 15:04 | 19 Jan, 2024 | 220.00 | 786 | ||
| 28 Nov 16:31 | 17 Jan, 2025 | 300.00 | 264 | ||
| 28 Nov 18:13 | 19 Apr, 2024 | 225.00 | 4 | ||
| 28 Nov 18:14 | 19 Apr, 2024 | 225.00 | 4 | ||
| 29 Nov 20:12 | 17 Jan, 2025 | 300.00 | 253 | ||
| 30 Nov 15:28 | 19 Jan, 2024 | 230.00 | 1336 | ||
| 30 Nov 19:41 | 19 Jan, 2024 | 220.00 | 785 | ||
| 01 Dec 16:48 | 19 Jan, 2024 | 225.00 | 299 | ||
| 01 Dec 19:22 | 19 Jan, 2024 | 235.00 | 809 |
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis. It also offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, and pemphigus vulgaris.
